On the Complexity of Reconfiguration in Systems with Legacy Components

International audienceIn previous works we have proved that component reconfig-uration in the presence of conflicts among components is non-primitive recursive, while it becomes poly-time if there are no conflicts and under the assumption that there are no components in the initial configuration. The case with non-empty initial configurations was left as an open problem, that we close in this paper by showing that, if there are legacy components that cannot be generated from scratch, the problem turns out to be PSpace-complete

Attributing and Referencing (Research) Software: Best Practices and Outlook from Inria

Software is a fundamental pillar of modern scientiic research, not only in computer science, but actually across all elds and disciplines. However, there is a lack of adequate means to cite and reference software, for many reasons. An obvious rst reason is software authorship, which can range from a single developer to a whole team, and can even vary in time. The panorama is even more complex than that, because many roles can be involved in software development: software architect, coder, debugger, tester, team manager, and so on. Arguably, the researchers who have invented the key algorithms underlying the software can also claim a part of the authorship. And there are many other reasons that make this issue complex. We provide in this paper a contribution to the ongoing eeorts to develop proper guidelines and recommendations for software citation, building upon the internal experience of Inria, the French research institute for digital sciences. As a central contribution, we make three key recommendations. (1) We propose a richer taxonomy for software contributions with a qualitative scale. (2) We claim that it is essential to put the human at the heart of the evaluation. And (3) we propose to distinguish citation from reference

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

The RD45 Collaboration

STATUS REPORT OF THE RD45 PROJECT 2 This document has been produced for the April 1998 LCB review of the RD45 project. In this paper, we present the status of the project, including a summary of the responses to the milestones 1 set at the 1997 review by the LCB, suggestions for future activities and a revised risk analysis of the current RD45 strategy. In addition, we describe activities undertaken within various experiments and projects, including NA45, COMPASS, ATLAS, CMS, ALICE, LHCb, BaBar, BELLE and Zeus. RD45 documents may be obtained through the Web (se

The RD45 Collaboration

2 This document has been produced for the October 1999 LCB review of the RD45 project. In this report, we present the status of the project, including a summary of the responses to the milestones 1 set at the 1998 review by the LCB, suggestions for future activities and a revised risk analysis of the current RD45 strategy. RD45 documents may be obtained through the Web vi